| Panic disorder. Pathophysiology and drug treatment. | |
| | |
MedLine Citation:
|
PMID: 7774510 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Advances over the past 2 decades in our understanding of the biology of panic disorder have paralleled a remarkable increase in the development of new pharmacological agents with antipanic effects. Although we can not presently use biological tests to help with our choice of therapeutic agent for individual patients, we can use this biological understanding in the development of overall pharmaco-therapeutic strategies. Current evidence does not support the hypothesis that panic disorder is associated with a primary disorder in one neurotransmitter system. Rather, the data suggest that the biological aetiology of panic disorder is related to abnormalities in the function of a variety of neurotransmitters including serotonin (5-hydroxytyrptamine; 5-HT), noradrenaline (norepinephrine), gamma-aminobutyric acid (GABA), dopamine, and cholecystokinin. It is likely, however, that panic disorder is a biologically heterogeneous condition and that biological subtypes may exist in which the primary abnormality may involve one or a few neurotransmitter systems. Currently, the data best support the hypothesis that pharmacotherapeutic agents with primary action at sites within the GABA and serotonin systems are the most effective in the treatment of panic disorder. Nevertheless, some patients will respond well to drugs with predominant activity in other systems, or may require pharmacotherapy designed to affect the function of more than 1 neurotransmitter. As our understanding of the biological aetiology of panic disorder evolves, the pharmacotherapeutic agents and strategies used in the treatment of this disorder will continue to evolve as well. |
| | |
Authors:
|
M R Johnson; R B Lydiard; J C Ballenger |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Drugs Volume: 49 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 1995 Mar |
Date Detail:
|
Created Date: 1995-07-11 Completed Date: 1995-07-11 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: NEW ZEALAND |
Other Details:
|
Languages: eng Pagination: 328-44 Citation Subset: IM |
Affiliation:
|
Department of Psychiatry, Medical University of South Carolina, Charleston, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Benzodiazepines
/
administration & dosage,
pharmacology,
therapeutic use* Cholecystokinin / physiology Cognitive Therapy / methods, standards Dopamine / physiology Humans Norepinephrine / physiology Panic Disorder / drug therapy, physiopathology*, therapy Serotonin / physiology Serotonin Uptake Inhibitors / administration & dosage, pharmacology, therapeutic use* Synaptic Transmission / physiology gamma-Aminobutyric Acid / physiology |
| Chemical | |
Reg. No./Substance:
|
0/Serotonin Uptake Inhibitors; 12794-10-4/Benzodiazepines; 50-67-9/Serotonin; 51-41-2/Norepinephrine; 56-12-2/gamma-Aminobutyric Acid; 9011-97-6/Cholecystokinin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Current management of acute myocardial infarction.
Next Document: Prospects for the use of antioxidant therapies.